Medicare Coverage for GLP-1 Drugs (Ozempic, Wegovy, Mounjaro): What Medigap Plans Cover in 2026

GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro have transformed treatment for type 2 diabetes and obesity — but their $900–$1,400/month price tags leave Medicare beneficiaries scrambling for answers. If you’re enrolled in a Medigap plan and wondering whether your supplement covers these blockbuster drugs, you need to understand the sharp line between what Medicare Parts A and B pay for versus what falls under Part D drug coverage.

Quick Answer

Medigap plans do NOT cover GLP-1 drugs like Ozempic, Wegovy, or Mounjaro. Medigap (Medicare Supplement Insurance) only supplements Original Medicare Parts A and B — it does not cover prescription drugs at all. GLP-1 medications are covered exclusively through Medicare Part D prescription drug plans. If you have diabetes, your Part D plan may cover Ozempic or Mounjaro with copays; if you’re seeking GLP-1 drugs for weight loss only, Medicare currently does not cover them at all.

Use our Medicare Supplement Penalty Calculator to estimate your total Medicare costs including Part D premiums alongside your Medigap plan.

Key Takeaways

• Medigap does not cover any prescription drugs — including GLP-1 medications like Ozempic, Wegovy, and Mounjaro. You need a standalone Part D plan or Medicare Advantage plan with drug coverage for these medications.
• Medicare covers GLP-1 drugs only for type 2 diabetes (FDA-approved indication). Coverage for weight loss alone is excluded under current Medicare Part D rules, though pending legislation could change this.
• GLP-1 drugs typically sit on Tier 3 (preferred brand) or Tier 5 (specialty) of Part D formularies, meaning you’ll pay a percentage coinsurance rather than a flat copay — often 25–33% of the drug’s cost.
• The Inflation Reduction Act’s $2,000 annual out-of-pocket cap (effective January 2025) significantly reduces what Part D enrollees pay for expensive drugs like GLP-1s — you’ll never pay more than $2,000/year in Part D costs in 2026.
• Manufacturer savings programs (NovoCare for Ozempic/Wegovy, Lilly Cares for Mounjaro/Zepbound) can provide GLP-1 drugs at reduced cost for eligible Medicare beneficiaries, though eligibility rules vary.
• Choosing the right Part D plan matters more than your Medigap plan when it comes to GLP-1 drug costs — compare formularies carefully during Annual Enrollment.

What Are GLP-1 Drugs and Why They Matter for Seniors

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medications originally developed to manage blood sugar in type 2 diabetes. They work by mimicking a hormone that stimulates insulin production, suppresses glucagon, slows digestion, and reduces appetite. The result: better blood sugar control and, often, significant weight loss.

The major GLP-1 and dual-agonist drugs on the market in 2026:

Drug	Active Ingredient	FDA-Approved For	Manufacturer	Approximate Monthly Cost
Ozempic	Semaglutide	Type 2 diabetes	Novo Nordisk	$950–$1,050
Wegovy	Semaglutide (higher dose)	Obesity/weight management	Novo Nordisk	$1,150–$1,350
Mounjaro	Tirzepatide	Type 2 diabetes	Eli Lilly	$1,000–$1,200
Zepbound	Tirzepatide (higher dose)	Obesity/weight management	Eli Lilly	$1,100–$1,400
Trulicity	Dulaglutide	Type 2 diabetes	Eli Lilly	$850–$950
Rybelsus	Semaglutide (oral)	Type 2 diabetes	Novo Nordisk	$900–$1,000

For seniors on Medicare, these drugs are especially relevant for several reasons:

1. Type 2 diabetes prevalence — Over 29% of Americans aged 65+ have diagnosed or undiagnosed diabetes, making GLP-1 drugs a common treatment consideration.
2. Obesity rates among seniors — Roughly 40% of adults 60+ have obesity, a condition that exacerbates cardiovascular disease, joint problems, and metabolic syndrome.
3. Cardiovascular benefits — Clinical trials have shown that semaglutide (Ozempic/Wegovy) reduces major cardiovascular events by 20% in high-risk patients, leading to increased interest among cardiologists treating Medicare-aged patients.
4. Kidney protection — Recent trials demonstrate GLP-1 drugs slow chronic kidney disease progression — critical for seniors, as CKD disproportionately affects the 65+ population.

The challenge is cost. Without insurance, a year of Ozempic runs $11,000–$13,000. For seniors living on Social Security and Medicare, understanding how coverage works — and where Medigap fits (or doesn’t) — is essential.

For help navigating your overall Medigap costs alongside drug expenses, see our Medicare Supplement Plan Cost Estimator.

Medicare Part D Coverage for GLP-1 Drugs

Prescription drug coverage for GLP-1 medications comes exclusively through Medicare Part D — either a standalone Prescription Drug Plan (PDP) paired with Original Medicare + Medigap, or a Medicare Advantage plan with built-in drug coverage (MAPD).

Formulary Tier Placement

Most Part D plans place GLP-1 drugs on one of these tiers:

• Tier 3 (Preferred Brand) — Some plans place Ozempic or Mounjaro here when they’re the preferred GLP-1 option. You’ll typically pay a percentage coinsurance (25–35%) rather than a flat copay.
• Tier 5 (Specialty) — Many plans place all GLP-1 injectables on the specialty tier, with coinsurance of 25–33%. For a $1,000/month drug, that’s $250–$330 per month out of pocket before reaching the coverage stages.

Important: Each Part D plan has its own formulary (drug list). A plan that covers Ozempic on Tier 3 may place Mounjaro on Tier 5, or vice versa. You cannot assume that because one GLP-1 drug is covered favorably, they all are.

Prior Authorization and Step Therapy

Part D plans commonly require prior authorization for GLP-1 drugs, meaning your doctor must demonstrate medical necessity before the plan will pay. Typical requirements include:

• Documented diagnosis of type 2 diabetes
• Trial and failure of metformin (step therapy)
• HbA1c levels above a certain threshold (usually 7.0% or higher)
• BMI documentation if the drug is being prescribed for diabetes with a comorbid obesity component

Step therapy means the plan requires you to try (and fail) cheaper alternatives first. For GLP-1 drugs, this usually means:

1. First-line: Metformin
2. Second-line: Sulfonylureas (glipizide, glyburide) or DPP-4 inhibitors (sitagliptin)
3. Third-line: GLP-1 receptor agonist approved

If your doctor believes you need a GLP-1 drug immediately due to your clinical situation, they can request a step therapy exception with supporting medical documentation.

Quantity Limits and Dose Restrictions

Part D plans typically impose quantity limits on GLP-1 drugs:

• Dispensed in 28-day or 30-day supplies only (no 90-day fills at most plans)
• Dose escalation must follow the manufacturer’s recommended titration schedule
• Plans may not cover more than one GLP-1 drug simultaneously

These restrictions exist partly because of the ongoing GLP-1 drug shortage, which has led some plans to tighten dispensing rules to ensure supply for patients with the greatest medical need.

Does Medigap Cover GLP-1 Drugs? (The Short Answer: No)

This is where many Medicare beneficiaries get confused. Here’s the clear breakdown:

What Medigap Actually Covers

Medigap plans supplement Original Medicare Parts A and B only. They help pay for:

• Part A deductibles and coinsurance (hospital stays, skilled nursing, hospice)
• Part B deductibles and coinsurance (doctor visits, outpatient procedures, durable medical equipment)
• Part B excess charges (Plan G and some other plans)
• Foreign travel emergency care (Plans G, N, and others)
• First three pints of blood

What Medigap Does NOT Cover

• Prescription drugs — No Medigap plan covers outpatient prescription medications. This was true before 2006 (when Part D was created) and remains true today. Plans H, I, and J that previously had limited drug coverage have been closed to new enrollees since 2006.
• Vision, dental, hearing — Routine care in these areas is not covered.
• Long-term care — Custodial nursing home care is excluded.

The bottom line: Whether you have Medigap Plan G, Plan N, Plan F (if eligible), or any other lettered plan, your GLP-1 drug costs are entirely separate from your Medigap coverage. Medigap may cover the doctor visit where your physician prescribes Ozempic (through Part B cost-sharing), but the drug itself falls under Part D.

If you’re trying to decide which Medigap plan pairs best with your overall healthcare needs, our Best Medigap Plans by Health Profile guide breaks down plan recommendations by medical condition.

Medicare Part D Plans with Best GLP-1 Coverage in 2026

While we can’t name specific plan benefit details (which change annually), here’s what to look for when comparing Part D plans for GLP-1 drug coverage during Annual Enrollment (October 15 – December 7):

What Makes a “Good” Part D Plan for GLP-1 Drugs

1. GLP-1 drugs on Tier 3 (not Tier 5) — Lower coinsurance percentage means less out of pocket per fill.
2. Preferred pharmacy networks — Some plans offer lower GLP-1 coinsurance at specific pharmacies (often mail-order or CVS/Walgreens).
3. Low deductible — Plans with a $0 or low deductible mean your GLP-1 coverage starts immediately. In 2026, the standard Part D deductible is $590, but many plans offer lower or zero deductibles.
4. Broad formulary — Plans that list multiple GLP-1 drugs give you and your doctor more flexibility if one drug causes side effects or is unavailable due to shortage.
5. Gap coverage (Extra Help eligibility) — If you qualify for the Part D Low-Income Subsidy (Extra Help), GLP-1 drug costs are dramatically reduced.

How to Compare Part D Plans for GLP-1 Coverage

The best tool is the Medicare Plan Finder at medicare.gov. Here’s how to use it effectively:

1. Enter your medications — list every GLP-1 drug your doctor might prescribe (Ozempic, Mounjaro, Trulicity, etc.)
2. Enter your preferred pharmacies
3. Sort results by “Lowest Drug + Premium Cost”
4. Check each plan’s formulary to confirm tier placement and prior auth requirements
5. Review the total annual estimated cost — this accounts for premiums, deductibles, and the drug costs through all coverage phases

Extra Help (Low-Income Subsidy) for GLP-1 Drugs

If your income is below approximately $22,000/year (individual) or $30,000/year (married couple) with limited assets, you may qualify for Extra Help through Social Security. This program:

• Eliminates or reduces the Part D deductible
• Reduces copays to $4.50–$11.20 per covered drug
• Eliminates the Part D coverage gap (donut hole)
• Provides continuous coverage with no late enrollment penalty

For GLP-1 drugs, Extra Help can reduce your costs from hundreds per month to under $15 per fill — a dramatic difference.

Cost Breakdown: Retail vs Part D vs Out-of-Pocket

Understanding the true cost of GLP-1 drugs requires looking at the full Part D coverage structure. In 2026, here’s how costs flow for a typical GLP-1 drug (using Ozempic at $1,000/month retail as an example):

Part D Coverage Phases in 2026

Phase	What You Pay	Approximate Duration
Deductible	Up to $590 (plan-specific)	January (1 month)
Initial Coverage	25% coinsurance (Tier 3) or 25–33% (Tier 5)	Until total drug costs reach ~$5,030
Coverage Gap (formerly Donut Hole)	25% of drug cost	Until your true out-of-pocket reaches $2,000
Catastrophic Coverage	$0 for the rest of the year	After $2,000 true OOP

Example — Ozempic at $1,000/month on Tier 3 (25% coinsurance):

• Month 1: $590 deductible + 25% of remaining drug cost ≈ $100 → ~$690
• Months 2–5: 25% coinsurance → $250/month
• After ~$2,000 true out-of-pocket: $0/month for the rest of the year

Total annual cost on Part D: ~$2,000 (thanks to the Inflation Reduction Act cap)

Without insurance: $12,000/year

That’s a savings of approximately $10,000 per year with Part D coverage — which is why having the right drug plan matters far more than Medigap when it comes to GLP-1 medications.

Before the Inflation Reduction Act, catastrophic coverage still required 5% coinsurance, meaning beneficiaries could pay $4,000–$5,000+ annually for GLP-1 drugs. The $2,000 cap that took effect January 2025 changed this dramatically.

For estimating your overall Medigap + Part D budget, our Medigap Premium Trends and Rate Forecast can help you project total costs.

The Inflation Reduction Act Impact on GLP-1 Drug Costs

The Inflation Reduction Act (IRA), signed in 2022, introduced several provisions that directly affect how much Medicare beneficiaries pay for GLP-1 drugs:

$2,000 Annual Out-of-Pocket Cap (Effective January 2025)

This is the single most impactful change for GLP-1 drug users. Starting in 2025, Part D enrollees will never pay more than $2,000 per year in out-of-pocket prescription drug costs. This cap applies automatically — no enrollment or paperwork required.

What this means for GLP-1 drug costs in 2026:

• Ozempic (diabetes): Previously ~$3,500–$5,000/year → Now capped at $2,000/year
• Mounjaro (diabetes): Previously ~$4,000–$5,500/year → Now capped at $2,000/year
• Any other GLP-1 drug: Capped at $2,000/year combined with all other Part D drugs

Monthly Payment Option (2025+)

The IRA also introduced a Monthly Medicare Drug Payment Plan (MDP), allowing beneficiaries to spread their out-of-pocket costs evenly across the year instead of front-loading expenses in January. This helps beneficiaries who previously struggled with large deductible payments in the first months of the year.

Drug Price Negotiation

While the IRA’s drug price negotiation program has started with other medications, GLP-1 drugs are not yet among the negotiated drugs for 2026. However, semaglutide and tirzepatide are strong candidates for future negotiation rounds, which could further reduce costs for Medicare beneficiaries in 2027 and beyond.

Insulin Cap at $35/month

Though not directly related to GLP-1 drugs, the IRA’s $35/month insulin cap is relevant for diabetic patients. If you’re currently on insulin and considering switching to or adding a GLP-1 drug, your insulin costs are now fixed at $35/month regardless of Part D phase.

When Medicare Covers GLP-1 for Diabetes vs. Weight Loss

This distinction is critical — and a source of enormous confusion for Medicare beneficiaries:

GLP-1 for Type 2 Diabetes: COVERED

If you have a diagnosed type 2 diabetes and your doctor prescribes a GLP-1 drug (Ozempic, Mounjaro, Trulicity, Rybelsus), Medicare Part D will cover it as long as:

• The drug is on your plan’s formulary
• Prior authorization is approved (if required)
• Step therapy requirements are met (if applicable)
• The prescription is for an FDA-approved diabetes indication

GLP-1 for Weight Loss Only: NOT COVERED

If you do not have type 2 diabetes and are prescribed Wegovy or Zepbound specifically for obesity or weight management, Medicare Part D does NOT cover it. This exclusion stems from a 2003 law (the Medicare Modernization Act) that prohibits Part D from covering drugs for “weight loss or weight gain.”

This means:

• A 68-year-old with type 2 diabetes can get Ozempic covered through Part D
• A 68-year-old with obesity but no diabetes cannot get Wegovy covered through Part D
• A 68-year-old with both type 2 diabetes AND obesity can get Ozempic or Mounjaro covered (since the diabetes indication qualifies)

Pending Legislation

Several bills have been introduced in Congress to expand Medicare coverage of anti-obesity medications:

• The Treat and Reduce Obesity Act (TROA) — Would allow Medicare Part D to cover FDA-approved anti-obesity drugs. This bill has been introduced in multiple congressional sessions but has not yet passed.
• The GLP-1 Access Act — Proposed legislation specifically targeting GLP-1 drug coverage expansion.

If either bill passes, it could open Part D coverage for Wegovy and Zepbound for Medicare beneficiaries with obesity. Monitor medicare.gov for updates.

How to Save on GLP-1 Drugs with Medicare

Even with Part D coverage and the $2,000 cap, GLP-1 drugs represent a significant expense. Here are strategies to reduce costs:

1. Manufacturer Savings Programs

Novo Nordisk (Ozempic, Wegovy, Rybelsus):

• NovoCare — Offers savings for commercially insured patients. Medicare beneficiaries generally don’t qualify for the main savings card, but Novo Nordisk offers a Patient Assistance Program (PAP) for low-income Medicare enrollees that can provide free medication.
• Contact: 866-310-7549 or novocare.com

Eli Lilly (Mounjaro, Trulicity, Zepbound):

• Lilly Cares — Patient assistance program that provides free medications to eligible Medicare beneficiaries with income below certain thresholds.
• LillyDirect — Offers access to affordable home delivery options.
• Contact: 800-545-5979 or lillycares.com

2. Extra Help (Low-Income Subsidy)

As discussed above, if you qualify for Extra Help, your GLP-1 copays drop to $4.50–$11.20 per fill. Apply through Social Security at ssa.gov or by calling 800-772-1213.

3. State Pharmaceutical Assistance Programs (SPAPs)

Many states offer pharmacy assistance programs for Medicare beneficiaries. These programs can help pay for Part D drugs that Medicare doesn’t fully cover. Check your state’s program at medicare.gov.

4. Switch to a Covered Alternative

If your prescribed GLP-1 drug is on a high tier, ask your doctor about alternatives that may be on a lower tier:

• Trulicity (dulaglutide) — Often on a lower tier than Ozempic or Mounjaro on some formularies, and it’s a once-weekly injectable GLP-1 with similar efficacy.
• Rybelsus (oral semaglutide) — The oral version of semaglutide may be on a different tier than injectable Ozempic at some plans.
• Older GLP-1 drugs — Victoza (liraglutide) has been available longer and may have better formulary positioning, though it’s daily rather than weekly.

5. 90-Day Supply via Mail Order

Some Part D plans offer lower coinsurance for 90-day mail-order fills compared to 30-day retail fills. While GLP-1 drugs often have quantity limits, check if your plan allows extended-day supply options.

6. Pharmaceutical Patient Navigation Services

Both Novo Nordisk and Eli Lilly offer patient navigation services that can help you understand your coverage options, appeal denied claims, and find financial assistance. These services are free and can be especially helpful for navigating prior authorization requirements.

Strategies for Medigap Policyholders to Manage GLP-1 Costs

Since Medigap doesn’t cover GLP-1 drugs, policyholders need a coordinated strategy:

Strategy 1: Optimize Your Part D Plan Selection

Your Medigap plan (G, N, or other) has zero impact on your GLP-1 drug costs. Focus your energy on selecting the best Part D plan for your medications:

• Use Medicare Plan Finder each year during Open Enrollment
• Compare total annual costs (premium + drug costs) across all available PDPs in your area
• Prioritize plans that place your specific GLP-1 drug on the lowest tier

Strategy 2: Bundle Your Healthcare Strategy

Think of your Medicare coverage as three separate but coordinated pieces:

1. Original Medicare (Parts A/B) — Covers hospital, doctor visits, and outpatient care
2. Medigap — Reduces your out-of-pocket costs for Parts A/B (but not drugs)
3. Part D — Covers GLP-1 drugs and all other prescriptions

All three work independently but need to be coordinated. If you’re spending $2,000/year on GLP-1 drugs through Part D, you may want a Medigap plan with lower premiums (like Plan N) to balance your total healthcare budget.

Our Medigap Plan G vs Plan N Comparison can help you weigh whether a lower-premium Medigap plan makes sense when you have significant drug costs.

Strategy 3: Appeal Denied GLP-1 Claims

If your Part D plan denies coverage for a GLP-1 drug, you have the right to appeal. Common reasons for denial and how to fight them:

• “Not medically necessary” — Have your doctor write a detailed letter explaining why this specific GLP-1 drug is needed, including failed alternatives and clinical justification.
• “Step therapy not met” — Request an exception if you’ve tried and failed alternatives in the past (even if not documented in your current plan’s records).
• “Drug not on formulary” — Request a formulary exception with your doctor’s supporting documentation.

The appeals process has specific timelines — your plan must respond within 72 hours for an expedited appeal or 30 days for a standard appeal.

Strategy 4: Coordinate with Your Medigap Plan’s Network Benefits

While Medigap doesn’t cover GLP-1 drugs, your Medigap plan does cover the doctor visits related to your diabetes management:

• Endocrinologist visits (Part B coinsurance covered by Medigap)
• Lab work and HbA1c testing (Part B coinsurance covered by Medigap)
• Nutrition counseling (covered under Part B for diabetes patients)
• Diabetes self-management training (covered under Part B)

These services are essential for ongoing GLP-1 treatment and are where your Medigap plan provides real value — just not for the drug itself.

Strategy 5: Reassess During Every Open Enrollment

Medicare plans change annually. Formularies shift, premiums adjust, and GLP-1 drug availability evolves. Make it a habit to:

• Review your Part D plan’s formulary each October
• Check whether your GLP-1 drug has moved to a different tier
• Compare your current plan against new options
• Verify that your Medigap plan’s premium is still competitive

The Medicare Supplement Switching Rules Checklist walks you through when and how to change your Medigap plan if your overall strategy needs adjusting.

The Future of GLP-1 Coverage Under Medicare

Several developments could significantly change GLP-1 drug coverage for Medicare beneficiaries in the coming years:

Generic and Biosimilar GLP-1 Drugs

Patents for some GLP-1 drugs will expire in the late 2020s, opening the door to biosimilar versions that could cost 30–50% less than brand-name drugs. The first semaglutide biosimilars are expected by 2028–2031, which could dramatically improve Part D coverage positioning.

Expanding FDA Indications

GLP-1 drugs are being studied for additional indications that could affect Medicare coverage:

• Cardiovascular risk reduction — The SELECT trial showed semaglutide reduces cardiovascular events. If FDA approves this indication specifically, it could influence Part D coverage decisions.
• Kidney disease — Ongoing trials may lead to CKD-specific approvals, potentially broadening coverage beyond diabetes alone.
• NAFLD/NASH — Non-alcoholic fatty liver disease is a growing concern among seniors, and GLP-1 drugs are showing promise in clinical trials.

Potential Medicare Coverage Expansion

If the Treat and Reduce Obesity Act or similar legislation passes, Medicare Part D could begin covering GLP-1 drugs for obesity — opening access to Wegovy and Zepbound for millions of seniors. The Congressional Budget Office has estimated this expansion could cost $35–$50 billion over a decade, which has slowed legislative progress.

Oral GLP-1 Alternatives

Several pharmaceutical companies are developing oral GLP-1 drugs that could be less expensive to manufacture and distribute than injectables. If approved and priced competitively, these could offer a more affordable pathway for Medicare beneficiaries.

Frequently Asked Questions

Does Medicare Supplement (Medigap) Plan G cover Ozempic?

No. Medigap Plan G — like all Medigap plans — only supplements Medicare Parts A and B. Ozempic is a prescription drug covered exclusively through Medicare Part D. Plan G will cover the Part B coinsurance for your doctor’s visit when Ozempic is prescribed, but the drug cost itself must be handled through your Part D prescription drug plan.

Can I get Wegovy covered by Medicare if I have diabetes?

Wegovy is specifically FDA-approved for weight management, not diabetes. If you have type 2 diabetes, your doctor would more appropriately prescribe Ozempic (same active ingredient, semaglutide, but approved for diabetes), which Part D covers when medically necessary. Using Wegovy “off-label” for diabetes when Ozempic is available is unlikely to be approved by your Part D plan.

How much does Ozempic cost on Medicare Part D in 2026?

With the Inflation Reduction Act’s $2,000 annual out-of-pocket cap in effect, your total Part D costs for Ozempic (and all other covered drugs combined) will not exceed $2,000 for the year. Monthly costs during the initial coverage phase typically run $250–$330 (25–33% coinsurance), but once you hit the $2,000 true out-of-pocket threshold, your cost drops to $0 for the remainder of the year.

What if my Part D plan denies coverage for my GLP-1 medication?

You have the right to file an appeal. Start by having your prescribing doctor submit a prior authorization with detailed clinical documentation showing medical necessity — including your diabetes diagnosis, previous medications tried and failed, and current HbA1c levels. If the initial denial is upheld, you can request a redetermination by an Independent Review Entity. About 40–50% of Medicare Part D appeals are ultimately successful.

Will Medicare ever cover GLP-1 drugs for weight loss?

Pending federal legislation — particularly the Treat and Reduce Obesity Act — would remove the current prohibition on Part D covering weight loss medications. If passed, Medicare could begin covering Wegovy, Zepbound, and other anti-obesity drugs. Additionally, if the FDA approves GLP-1 drugs for cardiovascular or kidney disease indications (beyond diabetes and obesity), Part D coverage could expand through those pathways as well.

Can I use manufacturer coupons for Ozempic or Mounjaro with Medicare?

Standard manufacturer savings cards typically exclude Medicare and Medicaid beneficiaries. However, both Novo Nordisk and Eli Lilly offer Patient Assistance Programs (PAPs) specifically for Medicare enrollees with limited income. Novo Nordisk’s PAP can provide free Ozempic to qualifying seniors, and Lilly Cares offers similar assistance for Mounjaro. Income eligibility thresholds are generally around $35,000–$55,000 for individuals.

Should I choose a different Medigap plan to save money for GLP-1 drugs?

Switching to a lower-premium Medigap plan (like Plan N instead of Plan G) won’t directly affect your GLP-1 drug costs, since Medigap doesn’t cover prescription drugs. However, if GLP-1 drug costs are straining your budget, reducing your Medigap premium by $30–$80/month could free up cash for Part D costs. Be aware that switching Medigap plans after your Open Enrollment Period typically requires medical underwriting, which could result in denial or higher premiums. Use our Medicare Supplement Penalty Calculator to model different scenarios.

Does the GLP-1 drug shortage affect Medicare coverage?

Yes. During periods of drug shortage, some Part D plans may impose additional restrictions — such as limiting fills to patients with the most urgent clinical need, requiring documentation of previous shortage-related interruptions, or directing patients to specific pharmacies with available supply. If your usual GLP-1 drug is unavailable, your doctor may need to prescribe an alternative GLP-1 medication or submit a non-formulary exception request to your Part D plan.

---

Understanding how GLP-1 drug coverage works with Medicare requires separating Medigap (Parts A/B supplement) from Part D (prescription drugs). While your Medigap plan won’t pay for Ozempic or Mounjaro, the combination of a well-chosen Part D plan and the Inflation Reduction Act’s $2,000 out-of-pocket cap makes these medications far more affordable than retail pricing suggests.

Ready to compare Medigap plan costs and find the right supplement for your budget? Use our free Medicare Supplement Penalty Calculator to estimate your total Medicare costs and find the most cost-effective plan for your situation.

Related reads

• Medicare Supplement Plan N vs Plan G: Total Cost Comparison 2026

  Compare Medicare Supplement Plan N vs Plan G total costs including premiums, copays, and out-of-pocket expenses in 2026. Find which plan saves more.

• Medigap for Widows and Widowers: How Losing Spouse Coverage Affects Your Medicare Supplement in 2026

  Lost your spouse? Learn how widowhood affects your Medicare Supplement coverage, guaranteed issue rights, and enrollment windows. Step-by-step guide to getting Medigap after losing spouse coverage in 2026.

• Medigap and the 2026 Medicare Part D $2,000 Out-of-Pocket Cap: How It Changes Your Supplement Strategy

  The Medicare Part D $2,000 out-of-pocket cap is now in effect. Learn how this landmark change impacts your Medigap plan choice, whether Plan G is still worth it, and how to recalculate your total healthcare costs in 2026.